MedTrace Logo

Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

NCT05044117 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2022-03-03

No results posted yet for this study

Summary

The purpose of this study is to investigate whether the addition of metronomic capecitabine to the standard treatment can improve prognosis in locoregionally advanced head and neck squamous cell carcinoma.

Conditions

Interventions

DRUG

Capecitabine

Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year

Sponsors & Collaborators

  • Fujian Medical University Union Hospital

    collaborator OTHER

  • Guangzhou Panyu Central Hospital

    collaborator OTHER

  • The Central Hospital of Yongzhou

    collaborator UNKNOWN

  • The First People's Hospital of Huaihua

    collaborator UNKNOWN

  • Hanzhong Central Hospital

    collaborator OTHER

  • Yichang Central People's Hospital

    collaborator OTHER

  • Affiliated Hospital of Guangdong Medical University

    collaborator OTHER

  • Jiangmen Central Hospital

    collaborator OTHER

  • Xiang Yang No.1 Peoples Hospital

    collaborator UNKNOWN

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Ying Sun, M.D. · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-18
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05044117 on ClinicalTrials.gov